PR Newswire Clinical TrialsOriginal article
iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
Trial StartapprovedNouvSight001Positive
AI Analysis
Summary
iRegene Therapeutics received clearance to begin clinical trials of NouvSight001, an off-the-shelf cell therapy for retinitis pigmentosa, in both the U.S. and China. This represents the company's advancement of another cell therapy program following its Parkinson's disease program.
Clinical Trial Data
Outcome Details
IND/clinical trial clearance in U.S. and China
Importance:6/10
Sentiment:
0.70
cell therapyoff-the-shelfretinitis pigmentosaclinical trial clearanceU.S.China
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 29, 2026 5:41 AM